Form 8-K - Current report:
SEC Accession No. 0001628280-22-003659
Filing Date
2022-02-24
Accepted
2022-02-24 08:15:06
Documents
15
Period of Report
2022-02-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vcel-20220224.htm   iXBRL 8-K 43171
2 EX-99.1 ex991earningsreleaseq42021.htm EX-99.1 141176
6 vericellogoa23.jpg GRAPHIC 48734
  Complete submission text file 0001628280-22-003659.txt   407857

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vcel-20220224.xsd EX-101.SCH 2521
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vcel-20220224_lab.xml EX-101.LAB 24451
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vcel-20220224_pre.xml EX-101.PRE 13054
9 EXTRACTED XBRL INSTANCE DOCUMENT vcel-20220224_htm.xml XML 10804
Mailing Address 64 SIDNEY ST. CAMBRIDGE MA 02139
Business Address 64 SIDNEY ST. CAMBRIDGE MA 02139 7349305555
Vericel Corp (Filer) CIK: 0000887359 (see all company filings)

EIN.: 943096597 | State of Incorp.: MI | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35280 | Film No.: 22666620
SIC: 2836 Biological Products, (No Diagnostic Substances)